By Bhanvi SatijaLONDON, Jan 29 (Reuters) - France's Sanofi, among the world's largest vaccine makers, said on Thursday that its vaccines sales would be "slightly negative" this year, partly due to U.S. policy changes under ​President Donald Trump. Sanofi is eyeing high-single-digit overall sales growth in 2026. He added, however, that it was a good time for dealmaking and that Sanofi would stick to ⁠its long-term bullish view on the industry. Chief Financial Officer François-Xavier Roger said that the company will not be able to offset the loss of sales once Dupixent, Sanofi's largest revenue driver, comes off patent. We take the necessary time to acquire assets that make sense from a strategic point of view," he said.